Armata Pharmaceuticals Secures $10M Loan for Clinical Trials

Armata Pharmaceuticals ( (ARMP) ) has provided an update.

On March 12, 2025, Armata Pharmaceuticals announced a secured credit agreement with Innoviva Strategic Opportunities LLC, providing a $10 million loan to advance its lead therapeutic phage candidates, AP-PA02 and AP-SA02. This financing will support the company’s clinical trials, including the Phase 1b/2a trial for AP-SA02, and preparations for an end-of-Phase 2 meeting with the FDA, while also extending the maturity dates of previous credit agreements to March 12, 2026.

More about Armata Pharmaceuticals

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing high-purity pathogen-specific bacteriophage therapeutics for treating antibiotic-resistant and difficult-to-treat bacterial infections. The company is advancing a broad pipeline of natural and synthetic phage candidates, including those targeting Pseudomonas aeruginosa and Staphylococcus aureus, supported by in-house phage-specific cGMP manufacturing for full commercialization.

YTD Price Performance: -4.10%

Average Trading Volume: 11,637

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $67.66M

For detailed information about ARMP stock, go to TipRanks’ Stock Analysis page.